FDA Approves Pediatric Risankizumab - Quiz - MDSpire

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Pediatric Risankizumab

  • by Kathryn Wighton

  • June 29, 2026

Related Content

Nonlinear Association of Serum Sodium with Urine Output in Postoperative Pediatric Cardiac Patients Receiving Furosemide: A Retrospective Study

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Virtual Care Remuneration Policy and Postdischarge Follow-Up Trends